{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T17:19:54Z","timestamp":1794503994448,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006955","name":"U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Survival in high-risk pediatric neuroblastoma has remained around 50% for the last 20 years, with immunotherapies and targeted therapies having had minimal impact. Here, we identify the small molecule CX-5461 as selectively cytotoxic to high-risk neuroblastoma and synergistic with low picomolar concentrations of topoisomerase I inhibitors in\u00a0improving survival in vivo in orthotopic patient-derived xenograft neuroblastoma mouse models. CX-5461 recently progressed through phase I clinical trial as a first-in-human inhibitor of RNA-POL I. However, we also use a comprehensive panel of in vitro and in vivo assays to demonstrate that CX-5461 has been mischaracterized and that its primary target at pharmacologically relevant concentrations, is in fact topoisomerase II beta (\n                    <jats:italic>TOP2B<\/jats:italic>\n                    ), not RNA-POL I. This is important because existing clinically approved chemotherapeutics have well-documented off-target interactions with TOP2B, which have previously been shown to cause both therapy-induced leukemia and cardiotoxicity\u2014often-fatal adverse events, which can emerge several years after treatment. Thus, while we show that combination therapies involving CX-5461 have promising anti-tumor activity in vivo in neuroblastoma, our identification of TOP2B as the primary target of CX-5461 indicates unexpected safety concerns that should be examined in ongoing phase II clinical trials in adult patients before pursuing clinical studies in children.\n                  <\/jats:p>","DOI":"10.1038\/s41467-021-26640-x","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T06:02:38Z","timestamp":1636437758000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma"],"prefix":"10.1038","volume":"12","author":[{"given":"Min","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard H.","family":"Chapple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manbir","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake E.","family":"Batchelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3653-2573","authenticated-orcid":false,"given":"Brandt C.","family":"Huddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaley B.","family":"Blankenship","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7382-9683","authenticated-orcid":false,"given":"Yingzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittney","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payton","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5518-7800","authenticated-orcid":false,"given":"Samuel W.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2608-2887","authenticated-orcid":false,"given":"Sivaraman","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Posgai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schuetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcie","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4889-8003","authenticated-orcid":false,"given":"Ravi","family":"Kalathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5564-1775","authenticated-orcid":false,"given":"Jon Patrick","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0556-6196","authenticated-orcid":false,"given":"M. Madan","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4027-4850","authenticated-orcid":false,"given":"Michael A.","family":"Dyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-585X","authenticated-orcid":false,"given":"Shondra M.","family":"Pruett-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Burgess B.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-3809","authenticated-orcid":false,"given":"Taosheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-9158","authenticated-orcid":false,"given":"Lucy A.","family":"Godley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2717-9365","authenticated-orcid":false,"given":"Scott C.","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8005-0427","authenticated-orcid":false,"given":"Elizabeth","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4503-6608","authenticated-orcid":false,"given":"John","family":"Easton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5128-0087","authenticated-orcid":false,"given":"Paul","family":"Geeleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"key":"26640_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev-med-011514-023121","volume":"66","author":"CU Louis","year":"2015","unstructured":"Louis, C. U. & Shohet, J. M. Neuroblastoma: molecular pathogenesis and therapy. Annu. Rev. Med. 66, 49\u201363 (2015).","journal-title":"Annu. Rev. Med."},{"key":"26640_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature25795","volume":"555","author":"X Ma","year":"2018","unstructured":"Ma, X. et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555, 371\u2013376 (2018).","journal-title":"Nature"},{"key":"26640_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40272-018-0297-x","volume":"20","author":"MF Wedekind","year":"2018","unstructured":"Wedekind, M. F., Denton, N. L., Chen, C.-Y. & Cripe, T. P. Pediatric cancer immunotherapy: opportunities and challenges. Pediatr. Drugs 20, 395\u2013408 (2018).","journal-title":"Pediatr. Drugs"},{"key":"26640_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2020.05.010","volume":"136","author":"L Moreno","year":"2020","unstructured":"Moreno, L. et al. Accelerating drug development for neuroblastoma: summary of the second neuroblastoma drug development Strategy forum from innovative therapies for children with cancer and international society of paediatric oncology Europe neuroblastoma. Eur. J. Cancer 136, 52\u201368 (2020).","journal-title":"Eur. J. Cancer"},{"key":"26640_CR5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"26640_CR6","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570\u2013575 (2012).","journal-title":"Nature"},{"key":"26640_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","volume":"137","author":"SM Federico","year":"2020","unstructured":"Federico, S. M. et al. A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies. Eur. J. Cancer 137, 204\u2013213 (2020).","journal-title":"Eur. J. Cancer"},{"key":"26640_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.celrep.2014.09.028","volume":"9","author":"E Stewart","year":"2014","unstructured":"Stewart, E. et al. Targeting the DNA repair pathway in Ewing sarcoma. Cell Rep. 9, 829\u2013840 (2014).","journal-title":"Cell Rep."},{"key":"26640_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nm.4036","volume":"22","author":"KH Kim","year":"2016","unstructured":"Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat. Med. 22, 128\u2013134 (2016).","journal-title":"Nat. Med."},{"key":"26640_CR10","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/s41588-018-0191-z","volume":"50","author":"AD Durbin","year":"2018","unstructured":"Durbin, A. D. et al. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat. Genet. 50, 1240\u20131246 (2018).","journal-title":"Nat. Genet."},{"key":"26640_CR11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.CD-12-0418","volume":"3","author":"A Puissant","year":"2013","unstructured":"Puissant, A. et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3, 308\u2013323 (2013).","journal-title":"Cancer Discov."},{"key":"26640_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR\u2013Cas9 screens. Nature 568, 511\u2013516 (2019).","journal-title":"Nature"},{"key":"26640_CR13","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","volume":"1","author":"SM Corsello","year":"2020","unstructured":"Corsello, S. M. et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nat. Cancer 1, 235\u2013248 (2020).","journal-title":"Nat. Cancer"},{"key":"26640_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s43018-020-0067-x","volume":"1","author":"HE Francies","year":"2020","unstructured":"Francies, H. E., McDermott, U. & Garnett, M. J. Genomics-guided pre-clinical development of cancer therapies. Nat. Cancer 1, 482\u2013492 (2020).","journal-title":"Nat. Cancer"},{"key":"26640_CR15","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","volume":"9","author":"A Khot","year":"2019","unstructured":"Khot, A. et al. First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study. Cancer Discov. 9, 1036\u20131049 (2019).","journal-title":"Cancer Discov."},{"key":"26640_CR16","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.3390\/ijms19092765","volume":"19","author":"CA Austin","year":"2018","unstructured":"Austin, C. A. et al. TOP2B: the first thirty years. Int. J. Mol. Sci. 19, 2765 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"26640_CR17","doi-asserted-by":"publisher","first-page":"8989","DOI":"10.1073\/pnas.1204406109","volume":"109","author":"IG Cowell","year":"2012","unstructured":"Cowell, I. G. et al. Model for MLL translocations in therapy-related leukemia involving topoisomerase II\u03b2-mediated DNA strand breaks and gene proximity. Proc. Natl Acad. Sci. USA 109, 8989\u20138994 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26640_CR18","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","volume":"18","author":"S Zhang","year":"2012","unstructured":"Zhang, S. et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med. 18, 1639\u20131642 (2012).","journal-title":"Nat. Med."},{"key":"26640_CR19","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","volume":"166","author":"F Iorio","year":"2016","unstructured":"Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740\u2013754 (2016).","journal-title":"Cell"},{"key":"26640_CR20","first-page":"5432","volume":"58","author":"X Liu","year":"1998","unstructured":"Liu, X., Turbyville, T., Fritz, A. & Whitesell, L. Inhibition of insulin-like growth factor I receptor expression in neuroblastoma cells induces the regression of established tumors in mice. Cancer Res. 58, 5432\u20135438 (1998).","journal-title":"Cancer Res."},{"key":"26640_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","volume":"22","author":"MJ Bywater","year":"2012","unstructured":"Bywater, M. J. et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer Cell 22, 51\u201365 (2012).","journal-title":"Cancer Cell"},{"key":"26640_CR22","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1038\/s41388-018-0611-7","volume":"38","author":"\u00d8H Hald","year":"2019","unstructured":"Hald, \u00d8. H. et al. Inhibitors of ribosome biogenesis repress the growth of MYCN-amplified neuroblastoma. Oncogene 38, 2800\u20132813 (2019).","journal-title":"Oncogene"},{"key":"26640_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2020.05.040","volume":"182","author":"M Olivieri","year":"2020","unstructured":"Olivieri, M. et al. A genetic map of the response to DNA damage in human cells. Cell 182, 481\u2013496. e421 (2020).","journal-title":"Cell"},{"key":"26640_CR24","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature08444","volume":"461","author":"FC Ledesma","year":"2009","unstructured":"Ledesma, F. C., El Khamisy, S. F., Zuma, M. C., Osborn, K. & Caldecott, K. W. A human 5\u2019-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 461, 674\u2013678 (2009).","journal-title":"Nature"},{"key":"26640_CR25","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3390\/genes10110868","volume":"10","author":"S Morimoto","year":"2019","unstructured":"Morimoto, S. et al. Type II DNA topoisomerases cause spontaneous double-strand breaks in genomic DNA. Genes 10, 868 (2019).","journal-title":"Genes"},{"key":"26640_CR26","doi-asserted-by":"publisher","first-page":"70481","DOI":"10.18632\/oncotarget.12026","volume":"7","author":"LJ Crawford","year":"2016","unstructured":"Crawford, L. J., Anderson, G., Johnston, C. K. & Irvine, A. E. Identification of the APC\/C co-factor FZR1 as a novel therapeutic target for multiple myeloma. Oncotarget 7, 70481 (2016).","journal-title":"Oncotarget"},{"key":"26640_CR27","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1021\/ml300110s","volume":"3","author":"M Haddach","year":"2012","unstructured":"Haddach, M. et al. Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics. ACS Med. Chem. Lett. 3, 602\u2013606 (2012).","journal-title":"ACS Med. Chem. Lett."},{"key":"26640_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0167-4781(98)00126-2","volume":"1400","author":"C Levine","year":"1998","unstructured":"Levine, C., Hiasa, H. & Marians, K. J. DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities. Biochim. Biophys. Acta (BBA)-Gene Struct. Expr. 1400, 29\u201343 (1998).","journal-title":"Biochim. Biophys. Acta (BBA)-Gene Struct. Expr."},{"key":"26640_CR29","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ejmech.2019.03.034","volume":"171","author":"X Liang","year":"2019","unstructured":"Liang, X. et al. A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. Eur. J. Med. Chem. 171, 129\u2013168 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"26640_CR30","unstructured":"Kaufmann, S. H. & Svingen, P. A. in DNA Topoisomerase Protocols, 253\u2212268 (Springer, 1999)."},{"key":"26640_CR31","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1093\/nar\/gkt171","volume":"41","author":"K Kiianitsa","year":"2013","unstructured":"Kiianitsa, K. & Maizels, N. A rapid and sensitive assay for DNA\u2013protein covalent complexes in living cells. Nucleic Acids Res. 41, e104\u2013e104 (2013).","journal-title":"Nucleic Acids Res."},{"key":"26640_CR32","doi-asserted-by":"publisher","first-page":"e79202","DOI":"10.1371\/journal.pone.0079202","volume":"8","author":"M Tammaro","year":"2013","unstructured":"Tammaro, M., Barr, P., Ricci, B. & Yan, H. Replication-dependent and transcription-dependent mechanisms of DNA double-strand break induction by the topoisomerase 2-targeting drug etoposide. PLoS One 8, e79202 (2013).","journal-title":"PLoS One"},{"key":"26640_CR33","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1073\/pnas.1921649117","volume":"117","author":"PM Bruno","year":"2020","unstructured":"Bruno, P. M. et al. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc. Natl Acad. Sci. USA 117, 4053\u20134060 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26640_CR34","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9, 338\u2013350 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"26640_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-10100-8","volume":"10","author":"V Prakash","year":"2019","unstructured":"Prakash, V. et al. Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. Nat. Commun. 10, 1\u201316 (2019).","journal-title":"Nat. Commun."},{"key":"26640_CR36","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1101\/gr.247759.118","volume":"30","author":"CJ Hsiao","year":"2020","unstructured":"Hsiao, C. J. et al. Characterizing and inferring quantitative cell cycle phase in single-cell RNA-seq data analysis. Genome Res. 30, 611\u2013621 (2020).","journal-title":"Genome Res."},{"key":"26640_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-20314-w","volume":"12","author":"A Warren","year":"2021","unstructured":"Warren, A. et al. Global computational alignment of tumor and cell line transcriptional profiles. Nat. Commun. 12, 1\u201312 (2021).","journal-title":"Nat. Commun."},{"key":"26640_CR38","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576. e516 (2017).","journal-title":"Cell"},{"key":"26640_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13993-7","volume":"11","author":"SW Brady","year":"2020","unstructured":"Brady, S. W. et al. Pan-neuroblastoma analysis reveals age-and signature-associated driver alterations. Nat. Commun. 11, 1\u201313 (2020).","journal-title":"Nat. Commun."},{"key":"26640_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ijc.31053","volume":"142","author":"F Rifatbegovic","year":"2018","unstructured":"Rifatbegovic, F. et al. Neuroblastoma cells undergo transcriptomic alterations upon dissemination into the bone marrow and subsequent tumor progression. Int. J. Cancer 142, 297\u2013307 (2018).","journal-title":"Int. J. Cancer"},{"key":"26640_CR41","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","volume":"180","author":"DP Nusinow","year":"2020","unstructured":"Nusinow, D. P. et al. Quantitative proteomics of the cancer cell line encyclopedia. Cell 180, 387\u2013402.e316 (2020).","journal-title":"Cell"},{"key":"26640_CR42","doi-asserted-by":"publisher","first-page":"34846","DOI":"10.18632\/oncotarget.5413","volume":"6","author":"SS Negi","year":"2015","unstructured":"Negi, S. S. & Brown, P. Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells. Oncotarget 6, 34846 (2015).","journal-title":"Oncotarget"},{"key":"26640_CR43","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41416-020-01158-z","volume":"124","author":"S Yan","year":"2021","unstructured":"Yan, S. et al. Targeting RNA Polymerase I transcription synergises with TOP1 inhibition in potentiating the DNA damage response in high-grade serous ovarian cancer. Br. J. Cancer 124, 616\u2013627 (2021).","journal-title":"Br. J. Cancer"},{"key":"26640_CR44","doi-asserted-by":"publisher","first-page":"eaat1719","DOI":"10.1126\/sciadv.aat1719","volume":"4","author":"ST Durant","year":"2018","unstructured":"Durant, S. T. et al. The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Sci. Adv. 4, eaat1719 (2018).","journal-title":"Sci. Adv."},{"key":"26640_CR45","doi-asserted-by":"publisher","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","volume":"22","author":"KM Foote","year":"2018","unstructured":"Foote, K. M. et al. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. J. Med. Chem. 22, 9889\u20139907 (2018).","journal-title":"J. Med. Chem."},{"key":"26640_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2000.tb07020.x","volume":"922","author":"LF Liu","year":"2000","unstructured":"Liu, L. F. et al. Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 922, 1\u201310 (2000).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"26640_CR47","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1200\/JCO.2001.19.5.1501","volume":"19","author":"U Vanhoefer","year":"2001","unstructured":"Vanhoefer, U. et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J. Clin. Oncol. 19, 1501\u20131518 (2001).","journal-title":"J. Clin. Oncol."},{"key":"26640_CR48","doi-asserted-by":"publisher","first-page":"44289","DOI":"10.18632\/oncotarget.6247","volume":"6","author":"FP Vendetti","year":"2015","unstructured":"Vendetti, F. P. et al. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget 6, 44289 (2015).","journal-title":"Oncotarget"},{"key":"26640_CR49","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model. Comput. Struct. Biotechnol. J. 13, 504\u2013513 (2015).","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"26640_CR50","doi-asserted-by":"publisher","first-page":"6142","DOI":"10.1158\/1078-0432.CCR-18-1381","volume":"24","author":"SG DuBois","year":"2018","unstructured":"DuBois, S. G. et al. Phase II trial of alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma. Clin. Cancer Res. 24, 6142\u20136149 (2018).","journal-title":"Clin. Cancer Res."},{"key":"26640_CR51","doi-asserted-by":"publisher","first-page":"6441","DOI":"10.1158\/1078-0432.CCR-17-0379","volume":"23","author":"SM Federico","year":"2017","unstructured":"Federico, S. M. et al. A pilot trial of humanized anti-GD2 monoclonal antibody (hu14. 18K322A) with chemotherapy and natural killer cells in children with recurrent\/refractory neuroblastoma. Clin. Cancer Res. 23, 6441\u20136449 (2017).","journal-title":"Clin. Cancer Res."},{"key":"26640_CR52","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/nchembio.1957","volume":"11","author":"JM Stokes","year":"2015","unstructured":"Stokes, J. M. & Brown, E. D. Chemical modulators of ribosome biogenesis as biological probes. Nat. Chem. Biol. 11, 924\u2013932 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"26640_CR53","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1177\/1533034617744955","volume":"16","author":"N Hein","year":"2017","unstructured":"Hein, N., Hannan, K. M., D\u2019Rozario, J. & Hannan, R. Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer. Technol. Cancer Res. Treat. 16, 736\u2013739 (2017).","journal-title":"Technol. Cancer Res. Treat."},{"key":"26640_CR54","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/j.ijbiomac.2019.08.109","volume":"139","author":"S Raje","year":"2019","unstructured":"Raje, S. & Barthwal, R. Molecular recognition of 3+ 1 hybrid human telomeric G-quadruplex DNA d-[AGGG (TTAGGG) 3] by anticancer drugs epirubicin and adriamycin leads to thermal stabilization. Int. J. Biol. Macromol. 139, 1272\u20131287 (2019).","journal-title":"Int. J. Biol. Macromol."},{"key":"26640_CR55","doi-asserted-by":"crossref","unstructured":"Raje, S., Pandav, K. & Barthwal, R. Dual mode of binding of anti cancer drug epirubicin to G-quadruplex [d-(TTAGGGT)] 4 containing human telomeric DNA sequence induces thermal stabilization. Bioorg. Med. Chem. 27, 115131 (2019).","DOI":"10.1016\/j.bmc.2019.115131"},{"key":"26640_CR56","doi-asserted-by":"crossref","unstructured":"Raje, S., Pandav, K. & Barthwal, R. Binding of anticancer drug adriamycin to parallel G-quadruplex DNA [d-(TTAGGGT)] 4 comprising human telomeric DNA leads to thermal stabilization: a multiple spectroscopy study. J. Mol. Recogn. 33, e2815 (2020).","DOI":"10.1002\/jmr.2815"},{"key":"26640_CR57","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ijbiomac.2017.12.134","volume":"111","author":"S Tripathi","year":"2018","unstructured":"Tripathi, S. & Barthwal, R. NMR based structure reveals groove binding of mitoxantrone to two sites of [d-(TTAGGGT)] 4 having human telomeric DNA sequence leading to thermal stabilization of G-quadruplex.Int. J. Biol. Macromol. 111, 326\u2013341 (2018).","journal-title":"Int. J. Biol. Macromol."},{"key":"26640_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-018-07882-8","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma. Nat. Commun. 10, 1\u201314 (2019).","journal-title":"Nat. Commun."},{"key":"26640_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-016-0009-6","volume":"8","author":"H Xu","year":"2017","unstructured":"Xu, H. et al. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1\/2 deficient tumours. Nat. Commun. 8, 1\u201318 (2017).","journal-title":"Nat. Commun."},{"key":"26640_CR60","doi-asserted-by":"publisher","first-page":"e65184","DOI":"10.7554\/eLife.65184","volume":"10","author":"M Bossaert","year":"2021","unstructured":"Bossaert, M. et al. Transcription-associated topoisomerase 2\u03b1 (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands. eLife 10, e65184 (2021).","journal-title":"eLife"},{"key":"26640_CR61","doi-asserted-by":"publisher","first-page":"eabb5953","DOI":"10.1126\/sciadv.abb5953","volume":"6","author":"S Ide","year":"2020","unstructured":"Ide, S., Imai, R., Ochi, H. & Maeshima, K. Transcriptional suppression of ribosomal DNA with phase separation. Sci. Adv. 6, eabb5953 (2020).","journal-title":"Sci. Adv."},{"key":"26640_CR62","doi-asserted-by":"publisher","first-page":"zcaa032","DOI":"10.1093\/narcan\/zcaa032","volume":"2","author":"J-C Mars","year":"2020","unstructured":"Mars, J.-C. et al. The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage, and cell inviability. NAR Cancer 2, zcaa032 (2020).","journal-title":"NAR Cancer"},{"key":"26640_CR63","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrm.2016.111","volume":"17","author":"Y Pommier","year":"2016","unstructured":"Pommier, Y., Sun, Y., Shar-yin, N. H. & Nitiss, J. L. Roles of eukaryotic topoisomerases in transcription, replication and genomic stability. Nat. Rev. Mol. Cell Biol. 17, 703 (2016).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"26640_CR64","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1073\/pnas.85.4.1060","volume":"85","author":"H Zhang","year":"1988","unstructured":"Zhang, H., Wang, J. C. & LIu, L. F. Involvement of DNA topoisomerase I in transcription of human ribosomal RNA genes. Proc. Natl Acad. Sci. USA 85, 1060\u20131064 (1988).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"26640_CR65","doi-asserted-by":"publisher","first-page":"12416","DOI":"10.1074\/jbc.M109.074211","volume":"285","author":"K Burger","year":"2010","unstructured":"Burger, K. et al. Chemotherapeutic drugs inhibit ribosome biogenesis at various levels. J. Biol. Chem. 285, 12416\u201312425 (2010).","journal-title":"J. Biol. Chem."},{"key":"26640_CR66","doi-asserted-by":"crossref","unstructured":"Leach, D. DNA Topology and Its Biological Effects, Monograph 20. Edited by Nicholas R. Cozzarelli and James C. Wang. Cold Spring Harbor Laboratory1990. 480 pages. Price $97. ISBN 0 87969 348 7. Genet. Res. 57, 284 (1991).","DOI":"10.1017\/S0016672300029451"},{"key":"26640_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-016-1043-8","volume":"17","author":"L Uusk\u00fcla-Reimand","year":"2016","unstructured":"Uusk\u00fcla-Reimand, L. et al. Topoisomerase II beta interacts with cohesin and CTCF at topological domain borders. Genome Biol. 17, 1\u201322 (2016).","journal-title":"Genome Biol."},{"key":"26640_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-16393-4","volume":"11","author":"E Sanij","year":"2020","unstructured":"Sanij, E. et al. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nat. Commun. 11, 1\u201318 (2020).","journal-title":"Nat. Commun."},{"key":"26640_CR69","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1126\/science.287.5450.131","volume":"287","author":"X Yang","year":"2000","unstructured":"Yang, X., Li, W., Prescott, E. D., Burden, S. J. & Wang, J. C. DNA topoisomerase II\u03b2 and neural development. Science 287, 131\u2013134 (2000).","journal-title":"Science"},{"key":"26640_CR70","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1534\/genetics.120.303169","volume":"215","author":"BY Frank","year":"2020","unstructured":"Frank, B. Y. et al. Characterization of the phototoxicity, chemigenetic profile, and mutational signatures of the chemotherapeutic CX-5461 in Caenorhabditis elegans. Genetics 215, 609\u2013621 (2020).","journal-title":"Genetics"},{"key":"26640_CR71","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"26640_CR72","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrg.2017.97","volume":"19","author":"JG Doench","year":"2018","unstructured":"Doench, J. G. Am I ready for CRISPR? A user\u2019s guide to genetic screens. Nat. Rev. Genet. 19, 67 (2018).","journal-title":"Nat. Rev. Genet."},{"key":"26640_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2014-15-1-r1","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 1\u201312 (2014).","journal-title":"Genome Biol."},{"key":"26640_CR74","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1158\/0008-5472.CAN-10-1728","volume":"71","author":"D Drygin","year":"2011","unstructured":"Drygin, D. et al. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. Cancer Res. 71, 1418\u20131430 (2011).","journal-title":"Cancer Res."},{"key":"26640_CR75","doi-asserted-by":"publisher","first-page":"5985","DOI":"10.2147\/OTT.S104513","volume":"9","author":"L Li","year":"2016","unstructured":"Li, L. et al. CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma. OncoTargets Ther. 9, 5985 (2016).","journal-title":"OncoTargets Ther."},{"key":"26640_CR76","first-page":"1805","volume":"130","author":"KH Maclachlan","year":"2017","unstructured":"Maclachlan, K. H. et al. Novel combination therapies with the RNA polymerase I inhibitor CX-5461 significantly improve efficacy in multiple myeloma. Blood 130, 1805\u20131805 (2017).","journal-title":"Blood"},{"key":"26640_CR77","doi-asserted-by":"publisher","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2015","unstructured":"Ritz, C., Baty, F., Streibig, J. C. & Gerhard, D. Dose-response analysis using R. PLoS One 10, e0146021 (2015).","journal-title":"PLoS One"},{"key":"26640_CR78","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski, A., He, L., Aittokallio, T. & Tang, J. SynergyFinder: a web application for analyzing drug combination dose\u2013response matrix data. Bioinformatics 33, 2413\u20132415 (2017).","journal-title":"Bioinformatics"},{"key":"26640_CR79","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/ng.2529","volume":"45","author":"TJ Pugh","year":"2013","unstructured":"Pugh, T. J. et al. The genetic landscape of high-risk neuroblastoma. Nat. Genet. 45, 279\u2013284 (2013).","journal-title":"Nat. Genet."},{"key":"26640_CR80","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1158\/2159-8290.CD-20-1230","volume":"11","author":"C McLeod","year":"2021","unstructured":"McLeod, C. et al. St. Jude Cloud: a pediatric cancer genomic data-sharing ecosystem. Cancer Discov. 11, 1082\u20131099 (2021).","journal-title":"Cancer Discov."},{"key":"26640_CR81","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568, 511\u2013516 (2019).","journal-title":"Nature"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26640-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26640-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26640-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T12:17:53Z","timestamp":1669983473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-26640-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["26640"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-26640-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.02.25.432934","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6468"}}